Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Its evidence base runs deep: in type-2 diabetes (SUSTAIN1) semaglutide cut HbA1c by 1.55 points[2], and in the 17,604-patient SELECT cardiovascular trial it reduced major cardiac events by 20% in adults with obesity and no diabetes[3]
By inhibiting DPP-4 activity, saxagliptin enhances endogenous incretin hormone levels, resulting in improved glucose-dependent insulin secretion, suppression of glucagon release, and better glycemic control
doi: 10.3275/7203 118 DealCLTonyMHybyeCAllenDBTauberMChristiansenJSet al
To circumvent this issue, we next used acute pharmacological antagonism of the incretin receptors in mouse islets
US$ 27.66
US$ 24.05
US$ 27.88
